A great article by @AndyT for Pharmaceutical Manufacturing and Packing Sourcer (PMPS). It examines how packaging systems can contribute to N-nitrosamine impurities in pharmaceutical products and why identifying these risks requires the right testing strategy.
Drawing on examples involving blister packaging and large-volume parenterals, Andrew explores potential sources of leachable nitrosamines and the role of targeted extractables and leachables testing in identifying and managing these risks.
The targeted analysis is a real key component to this. The non-targeted analysis that is traditionally used in E&L studies is unlikely to have the sensitivity needed for nitrosamines.
Thank you for sharing. This is really interesting and also troubling. As more questions arise in the course of E&L evaluation/analytics which need to be covered. Or at least should be taken into consideration.
Maybe a contreversial comment/question at this point:
I wonder how far the analytical expert should go to cover every possibility or should this expert start arguing and taking a more risk-based approach (still evidence based) to show “authorities” alternative approaches based on plausibility, expertise, common sense/knowledge.
I think this right here is the primary problem in E&L today. If we really think about it, everything is risk based, especially when there are a lot of unknowns. I’ve said frequently that if we wanted to be 0 risk in our QC testing, we would test literally every tablet manufactured and never have a product. We’re relying on a risk assessment to say that our sample is representative. That risk assessment is based on sound science and standardized expectations.
In E&L there are not enough standardized expectations. So, the level of exploration and scientific rigor varies wildly. Somewhat separately, we see drastically different results in round-robin studies.